---
title: Slow Parkinson progression through exercise
nct_id: NCT06193252
phase: NA
status: RECRUITING
sponsor: Radboud University Medical Center
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06193252"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06193252"
last_fetched: "2026-05-10T14:03:02.029Z"
source: "Parkinson's Pathways (curated)"
---
# Slow Parkinson progression through exercise

**Goal (in five words):** Slow Parkinson progression through exercise

**Official Title:** Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

**Trial ID:** [NCT06193252](https://clinicaltrials.gov/study/NCT06193252)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Radboud University Medical Center
- **Target Enrollment:** 110 participants
- **Start Date:** 2024-01-15
- **Completion Date:** 2027-12-01
- **Conditions:** Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Parkinsonian Disorders, REM Sleep Behavior Disorder, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases
- **Interventions:** Increase of physical activity volume and intensity with the use of a motivational smartphone application
- **Intervention Types:** BEHAVIORAL

## Summary For Families

The goal is to slow or delay the shift from idiopathic REM sleep behavior disorder into Parkinson's disease and related synucleinopathies by boosting early brain resilience. The approach is a non-drug exercise program delivered through a motivational smartphone app with Fitbit monitoring that gradually increases the volume and intensity of physical activity, the idea being that more and stronger aerobic and movement training can improve blood flow, lower inflammation, and support neural circuits that help preserve motor and cognitive function, and because it is a lifestyle intervention it does not involve medications or interact with levodopa. They are enrolling Dutch-speaking adults aged 50 and older who have iRBD, can walk independently, are not already in a high activity range, own a compatible smartphone, live in the community, and do not have a diagnosed neurodegenerative disease, frequent weekly falls, or problems using a phone.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* previously diagnosed with iRBD meeting the following criteria according to the International Classification of Sleep Disorders (ICSD-3)
* able to understand the Dutch language
* being able to walk independently inside the home without the use of a walking aid
* Not in a high physical activity range during the 4-week eligibility and baseline period
* in possession of a suitable smartphone compatible with the Slow-SPEED app, the Fitbit app and the Roche PD Research Mobile application.

Exclusion Criteria:

* clinically diagnosed or self-reported diagnosis neurodegenerative disease;
* self-reported weekly falls in the previous 3 months;
* dexterity problems or cognitive impairments hampering smartphone use;
* if they do not wish to be informed about an increased risk of developing diseases associated with iRBD
* if individual is not community-dwelling

Exclusion criteria for MRI only:

* history of epilepsy, structural brain abnormalities (i.e. stroke, traumatic defects, large arachnoid cysts) or brain surgery
* claustrophobia
* implanted electrical devices (i.e. pacemaker, deep-brain stimulator (DBS), neurostimulator)
* metal implants (such as prosthetics, ossicle prosthesis, metal plates or other non-removable metal part) or metal splinters
* pregnancy
* fear for incidental finding
```

## Locations (1)

- Radboud University Medical Center, Nijmegen, Gelderland, Netherlands _(51.8425, 5.8528)_
  - Thomas Oosterhof, MSc — (CONTACT) — +31631647857 — slow-speed@radboudumc.nl

## Central Contacts

- Thomas Oosterhof, MSc — (CONTACT) — 0031631647857 — thomas.oosterhof@radboudumc.nl

---

*Canonical: https://parkinsonspathways.com/trial/NCT06193252*  
*HTML version: https://parkinsonspathways.com/trial/NCT06193252*  
*Source data: https://clinicaltrials.gov/study/NCT06193252*